Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.38 |
| ▸ | AURKA | O14965 | 4/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL208496 | 0.91 | PRMT5 (0.44) | CHEK2PRMT5DGAT1AURKATNKS | |
| SCHEMBL209520 | 0.88 | AURKA (0.40) | CHEK2PRMT5DGAT1AURKA | |
| SCHEMBL210610 | 0.87 | MEN1 (0.43) | DGAT1AURKATNKSTNKS2 | |
| SCHEMBL16152489 | 0.85 | AURKA (0.38) | CHEK2PRMT5FFAR4DGAT1AURKA | |
| SCHEMBL4789897 | 0.80 | AURKA (0.42) | AURKA | |
| SCHEMBL4790505 | 0.80 | AURKA (0.54) | AURKA | |
| SCHEMBL210988 | 0.79 | PRMT5 (0.44) | PRMT5TNKSTNKS2 | |
| SCHEMBL211891 | 0.79 | AURKA (0.56) | AURKA | |
| SCHEMBL14495800 | 0.78 | MEN1 (0.39) | PRMT5DGAT1AURKA | |
| SCHEMBL16152488 | 0.77 | MEN1 (0.38) | DGAT1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | CHEK2 76/4885PRMT5 312/4885FFAR4 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.